
ICON Public Limited Company ICLR
€ 94.43
3.33%
Geschäftsbericht 2024
hinzugefügt 04.04.2026
ICON Public Limited Company Betriebsaufwand 2011-2026 | ICLR
Betriebsaufwand Jährlich ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 408 M | 398 M | 392 M | 385 M | 385 M | 384 M | 389 M | 360 M | 324 M | 295 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 408 M | 295 M | 372 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.99 B | $ 117.5 | 2.1 % | $ 35.7 B | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 16.83 | 4.86 % | $ 897 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 1.45 | 5.84 % | $ 1.93 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 23.53 | 1.73 % | $ 654 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 178.34 | 1.53 % | $ 8.84 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 2.2 | -4.35 % | $ 9.73 M | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 195.87 | 3.3 % | $ 140 B | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
3.69 B | $ 126.96 | 4.99 % | $ 20.2 B | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 15.3 | 6.03 % | $ 463 M | ||
|
Guardant Health
GH
|
226 M | $ 82.21 | 4.59 % | $ 10.3 B | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
9.98 M | $ 2.85 | 5.95 % | $ 92.5 K | ||
|
Medpace Holdings
MEDP
|
118 M | $ 501.23 | 1.56 % | $ 14.5 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.08 | -2.8 % | $ 4.78 M | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 28.55 | 0.87 % | $ 20 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 264.18 | 1.25 % | $ 22 B | ||
|
Celcuity
CELC
|
172 M | $ 120.4 | 2.78 % | $ 5.63 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 4.59 | 5.52 % | $ 425 M | ||
|
NeoGenomics
NEO
|
430 M | $ 8.0 | 4.03 % | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 9.14 | -2.97 % | $ 1.98 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 81.67 | 1.34 % | $ 5.51 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
Natera
NTRA
|
258 M | $ 201.9 | 4.6 % | $ 19.9 B | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 192.91 | 0.73 % | $ 21.4 B | ||
|
ENDRA Life Sciences
NDRA
|
5.76 M | $ 5.19 | 5.06 % | $ 4.08 M | ||
|
National Research Corporation
NRC
|
38.5 M | $ 16.82 | 2.03 % | $ 376 M | ||
|
Organovo Holdings
ONVO
|
23.3 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.45 | 8.21 % | $ 435 M | ||
|
Psychemedics Corporation
PMD
|
11.3 M | - | -1.84 % | $ 15.3 M |